1:26 PM
Nov 10, 2017
 |  BC Week In Review  |  Clinical News  |  Clinical Status

vTv starts Phase Ib/II trial of TTP399 for T1D

vTv Therapeutics Inc. (NASDAQ:VTVT) began the Phase Ib/II simplici-T1 trial to evaluate TTP399 (GKI-399) as an add-on to insulin therapy in about 126 adults with Type I diabetes.

The double-blind, U.S. trial's primary endpoint is the change in HbA1c from baseline at 12...

Read the full 194 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >